Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Drug Safety Update - May 2010

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for May 2010 (PDF).

This issue contains drug safety advice in the following areas:

  • Possibility of an increased risk of persistent pulmonary hypertension in the newborn of mothers receiving selective serotonin reuptake inhibitors (SSRIs) and selective noradrenaline reuptake inhibitors (SNRIs) in pregnancy
  • Increased risk of bone fractures in patients receiving SSRIs and tricyclic antidepressants (TCAs)
  • An interaction between carbapenem antibiotics and valproic acid that results in decreased blood levels of valproic acid
  • Reminder to prescribe oral tacrolimus by brand name to avoid medication errors as a result of brand swapping since the brand are not interchangeable
  • Warning about the increased risk of myopathy in patients receiving the highest licensed dose of simvastatin (80mg)

Action: Clinicians will find this publication to be a useful review of current issues in drug safety.

Share 'Drug Safety Update - May 2010' on Email Share 'Drug Safety Update - May 2010' on Delicious Share 'Drug Safety Update - May 2010' on Digg Share 'Drug Safety Update - May 2010' on Facebook Share 'Drug Safety Update - May 2010' on Google+ Share 'Drug Safety Update - May 2010' on reddit Share 'Drug Safety Update - May 2010' on StumbleUpon Share 'Drug Safety Update - May 2010' on Twitter

atomic-wealth

No Comments to “Drug Safety Update - May 2010”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,524 spam comments.

atomic-wealth
fond-illness
summer